OKYO PHARMA LTD (OKYO) Forecast, Price Target & Analyst Ratings
NASDAQ:OKYO • GG00BMFG5F62
1.66 USD
-0.03 (-1.78%)
Last: Mar 6, 2026, 06:41 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for OKYO PHARMA LTD (OKYO).
Forecast Snapshot
Consensus Price Target
$8.16
+ 391.57% Upside
Next Earnings Forecast
Release DateN/A
PeriodQ3 / 2026
EPS Estimate-£0.05
Revenue Estimate
ChartMill Buy Consensus
82.22%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$8.16
Upside
+ 391.57%
From current price of $1.66 to mean target of $8.16, Based on 9 analyst forecasts
Low
$5.05
Median
$7.14
High
$13.65
Price Target Revisions
1 Month
-4.00%
3 Months
-20.00%
Price Target Summary
9 analysts have analysed OKYO and the average price target is 8.16 USD. This implies a price increase of 391.57% is expected in the next year compared to the current price of 1.66.
The average price target has been revised downward by 20% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.22%
OKYO was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about OKYO.
In the previous month the buy percentage consensus was at a similar level.
OKYO was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-20 | Piper Sandler | Initiate | Overweight |
| 2025-12-08 | B. Riley Securities | Initiate | Buy |
| 2025-09-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-01-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-02 | HC Wainwright & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ3 / 2026
EPS Estimate-£0.05
Revenue EstimateN/A
Revenue Q2QN/A
EPS Q2Q0.00%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | |||||||||
| EBITDA YoY % growth | -20.16M | -3.48M 82.74% | -1.21M 65.23% | -2.56M -111.57% | -4.55M -77.73% | -13.183M -189.75% | -15.746M -19.44% | -7.089M 54.98% | N/A | N/A | N/A | |
| EBIT YoY % growth | -20.16M | -3.48M 82.74% | -1.21M 65.23% | -2.57M -112.40% | -4.55M -77.04% | -13.187M -189.83% | -15.75M -19.43% | -7.092M 54.97% | N/A -38.79% | N/A -103.11% | N/A -29.59% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A -4,543.98% | N/A 57.50% | N/A -25.49% | N/A -59.38% | N/A 5.88% |
All data in GBP
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 26 | Q4 / 26 | |
|---|---|---|
| EPS Q2Q % growth | -0.05 | -0.08 -60.00% |
| Revenue Q2Q % growth | N/A | |
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -2.244M -29.41% | -3.57M 4.87% |
All data in GBP
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-23.47%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
OKYO PHARMA LTD / OKYO Forecast FAQ
What is the price target for OKYO stock?
9 analysts have analysed OKYO and the average price target is 8.16 USD. This implies a price increase of 391.57% is expected in the next year compared to the current price of 1.66.